Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries, 318-320 [2019-28419]
Download as PDF
318
Federal Register / Vol. 85, No. 2 / Friday, January 3, 2020 / Notices
Dated: December 30, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019–28417 Filed 1–2–20; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–1423]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Imports and
Electronic Import Entries
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) is
announcing an opportunity for public
comment on the proposed collection of
certain information by the Agency.
Under the Paperwork Reduction Act of
1995 (PRA), Federal Agencies are
required to publish notice in the
Federal Register concerning each
proposed collection of information,
including each proposed renewal of an
existing collection of information, and
to allow 60 days for public comment in
response to the notice. This notice
solicits comments on information
collection associated with FDA import
activities.
SUMMARY:
Submit either electronic or
written comments on the collection of
information by March 3, 2020.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before March 3,
2020. The https://www.regulations.gov
electronic filing system will accept
comments until 11:59 p.m. Eastern Time
at the end of March 3, 2020. Comments
received by mail/hand delivery/courier
(for written/paper submissions) will be
considered timely if they are
postmarked or the delivery service
acceptance receipt is on or before that
date.
DATES:
jbell on DSKJLSW7X2PROD with NOTICES
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
VerDate Sep<11>2014
17:29 Jan 02, 2020
Jkt 250001
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2013–N–1423 for ‘‘Submission of Food
and Drug Administration Import Data in
the Automated Commercial
Environment.’’ Received comments,
those filed in a timely manner (see
ADDRESSES), will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Dockets Management Staff
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
PO 00000
Frm 00022
Fmt 4703
Sfmt 4703
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Domini Bean, Office of Operations,
Food and Drug Administration, Three
White Flint North, 10A–12M, 11601
Landsdown St., North Bethesda, MD
20852, 301–796–5733, PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3521), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
E:\FR\FM\03JAN1.SGM
03JAN1
Federal Register / Vol. 85, No. 2 / Friday, January 3, 2020 / Notices
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Imports and Electronic Import Entries
OMB Control Number 0910–0046—
Revision
This information collection supports
Agency regulations in 21 CFR part 1,
which govern FDA import activities.
Specifically, the regulations prescribe
the required data elements that
respondents must submit when
importing, or offering for import, an
FDA-regulated article into the United
States. The data elements allow FDA to
continue to meet its responsibilities
pertaining to current submission
requirements established by the U.S.
Customs and Border Protection (CBP)
related to the submission of entry
information in using its Automated
Commercial Environment (ACE) system,
or any CBP-authorized electronic data
interchange (EDI) system. Respondents
(ACE filers) submit important and
useful information about FDA-regulated
products being imported or offered for
import into the United States so that we
may effectively and efficiently review
products and determine their
admissibility. In addition, and as set
forth in the regulations, certain product
types are subject to additional data
elements (for example, 21 CFR 1.75
prescribes additional data elements for
radiation-emitting products), as well as
those data elements applicable to all
products.
We are revising the information
collection to provide for a weekly entry
filing program (WEF). More detailed
information on Foreign Trade Zones
(FTZ)/WEF, is available at https://
www.fda.gov/industry/import-basics/
foreign-trade-zonesweekly-entry-filing.
The WEF program, which is available
for some FDA-regulated products,
allows entry filers to file a single entry
estimating the amount of merchandise
anticipated to be removed from a FTZ
and offered for U.S. consumption during
a 7-day period. To participate, we
recommend respondents who wish to
file a weekly entry of FDA-regulated
products with CBP, first request a
preliminary assessment from FDA. As
part of this assessment, we recommend
submission of the following
information:
• FDA Import Division(s) 1 with
geographic oversight over the FTZ
location;
• Identification of whether products
are manufactured or stored in the FTZ;
• FTZ site/subzone number and
address;
• Importer of Record (IOR) Facility
Establishment Identifier (FEI), if known;
• Manufacturer FEI, if known; and
• Port of entry.
The division information is necessary
so that we can appropriately route the
submission within the Agency.
Information on whether the product is
stored or manufactured in the zone is
necessary for FDA to determine the
applicable admissibility requirements.
319
The FTZ and port information is
necessary to ensure that basic
requirements in 19 CFR 146 are met.
The IOR and manufacturer FEI
information is requested by FDA to
expedite the admissibility review.
Requests to participate in the WEF
process are submitted to the FDA Import
Division Office covering the intended
port of entry.
We are also revising the information
collection to include our Import Trade
Auxiliary Communication System
(ITACS), currently approved under
OMB control number 0910–0842. The
ITACS is used by the import trade
community and was implemented to
improve communication with FDA. By
utilizing ITACS, respondents to the
information collection have the ability
to establish an account and
electronically check the status of FDAregulated entries and lines, submit entry
documentation, submit the location of
goods availability for those lines
targeted for examination by the FDA,
and check the estimated laboratory
analysis completion dates for lines
which have been sampled. For further
information regarding ITACS, please
visit our website at https://www.fda.gov/
industry/import-systems/itacs.
Description of Respondents:
Respondents to the information
collection are domestic and foreign
importers of FDA-regulated articles
being imported or offered for import
into the United States and entry filers
who submit import entries on behalf of
these importers.
We estimate the burden of the
information collection as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
21 CFR part 1; subpart D
Average
burden per
response
Total annual
responses
Total hours
Importers submission of data elements (preparing the required information).
Entry filers (unique lines only) ...............................................
WEF participants ...................................................................
ITACS; creation of account ...................................................
85,480
10.05
859,074
0.05576 hours (3.346 minutes) .........
47,902
3,419
15
500
12,196
1
1
41,698,124
15
1
0.04466 hours (2.68 minutes) ...........
0.87 hours (52 minutes) ....................
1 ........................................................
1,862,238
13.05
250
Total ................................................................................
......................
........................
42,557,214
...........................................................
1,910,403
1
jbell on DSKJLSW7X2PROD with NOTICES
Number of
responses per
respondent
There are no capital or operational and maintenance costs associated with the information collection.
An importer of record may be the
owner or purchaser of the article being
imported or offered for import, or a
customs broker licensed by CBP under
19 U.S.C. 1641 who has been designated
by the owner, purchaser, or consignee to
file the import entry. There is only one
importer of record per entry. We are
updating the number of responses and
respondents since last OMB review of
the information collection to reflect the
best data available to the Agency from
January 1, 2018, to December 31, 2018.
Using these numbers, we update the
number of importers to 85,480 and the
number of entry filers to 3,419. We
retain our currently approved estimate
with regard to the number of responses
per respondent and time per response as
representative of the industry average.
Persons wishing to file weekly entries
of FDA regulated products are
encouraged to provide the information
identified so that FDA can conduct a
1 Some FTZs are covered by multiple Import
Divisions.
VerDate Sep<11>2014
17:29 Jan 02, 2020
Jkt 250001
PO 00000
Frm 00023
Fmt 4703
Sfmt 4703
E:\FR\FM\03JAN1.SGM
03JAN1
320
Federal Register / Vol. 85, No. 2 / Friday, January 3, 2020 / Notices
jbell on DSKJLSW7X2PROD with NOTICES
preliminary admissibility assessment of
the associated products and firms. This
submission typically contains the
information FDA requests for multiple
products (i.e., the respondent wishes to
file weekly entries for multiple products
and submits the information for each
product together). Generally,
submissions involving multiple
products are significantly less
burdensome on a per-product basis. We
estimate that the burden for each
product in a WEF submission is
approximately 52.5 minutes, for a total
of 13.125 hours annually. Depending on
the product and scale of submission,
this estimated burden can fall to as low
as 15 minutes per product. The reason
why this burden can be significantly
higher than an ACE submission is that
the WEF submission is done manually,
typically through a spreadsheet. Filers
submitting in ACE typically use
software that is developed to
specifically automate and expedite the
entry submission process and allows
filers to automatically upload entry
information. While the WEF submission
includes an initial one-time submission
burden, we expect reduced burden over
a long term because filers can
subsequently submit one entry covering
multiple withdrawals from the FTZ in
any given seven-day period.
Finally, since developing and
implementing ITACS we believe that
most respondents to the information
collection have realized the one-time
burden associated with creating an
account and we have therefore adjusted
our estimate downward by 2,500 hours.
At the same time, we retain our estimate
that 500 new accounts will be
established annually for a total of 250
burden hours.
Cumulatively these changes and
adjustments result in a reduction in
annual responses by 40,112,208, and an
increase in burden hours by 124,891.
These changes and adjustments reflect
the realization of one-time burden
associated with conforming to new CBP
electronic reporting requirements since
last OMB approval of the information
collection that we believe no longer
applies, together with the consolidation
of related information collection
activities associated with ITACS.
Dated: December 30, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019–28419 Filed 1–2–20; 8:45 am]
BILLING CODE 4164–01–P
VerDate Sep<11>2014
17:29 Jan 02, 2020
Jkt 250001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–N–3535]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Special Protocol
Assessment; Guidance for Industry
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA, Agency, or we) is
announcing an opportunity for public
comment on the proposed collection of
certain information by the Agency.
Under the Paperwork Reduction Act of
1995 (PRA), Federal Agencies are
required to publish notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information, and
to allow 60 days for public comment in
response to the notice. This notice
solicits comments on the information
collection in the April 2018 guidance
for industry entitled ‘‘Special Protocol
Assessment’’ (Revision 1).
DATES: Submit either electronic or
written comments on the collection of
information by March 3, 2020.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before March 3,
2020. The https://www.regulations.gov
electronic filing system will accept
comments until 11:59 p.m. Eastern Time
at the end of March 3, 2020. Comments
received by mail/hand delivery/courier
(for written/paper submissions) will be
considered timely if they are
postmarked or the delivery service
acceptance receipt is on or before that
date.
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. 2016–N–
3535 for ‘‘Special Protocol Assessment;
Guidance for Industry.’’ Received
comments, those filed in a timely
manner (see ADDRESSES), will be placed
in the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
E:\FR\FM\03JAN1.SGM
03JAN1
Agencies
[Federal Register Volume 85, Number 2 (Friday, January 3, 2020)]
[Notices]
[Pages 318-320]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-28419]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-N-1423]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Imports and Electronic Import Entries
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
an opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(PRA), Federal Agencies are required to publish notice in the Federal
Register concerning each proposed collection of information, including
each proposed renewal of an existing collection of information, and to
allow 60 days for public comment in response to the notice. This notice
solicits comments on information collection associated with FDA import
activities.
DATES: Submit either electronic or written comments on the collection
of information by March 3, 2020.
ADDRESSES: You may submit comments as follows. Please note that late,
untimely filed comments will not be considered. Electronic comments
must be submitted on or before March 3, 2020. The https://www.regulations.gov electronic filing system will accept comments until
11:59 p.m. Eastern Time at the end of March 3, 2020. Comments received
by mail/hand delivery/courier (for written/paper submissions) will be
considered timely if they are postmarked or the delivery service
acceptance receipt is on or before that date.
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2013-N-1423 for ``Submission of Food and Drug Administration Import
Data in the Automated Commercial Environment.'' Received comments,
those filed in a timely manner (see ADDRESSES), will be placed in the
docket and, except for those submitted as ``Confidential Submissions,''
publicly viewable at https://www.regulations.gov or at the Dockets
Management Staff between 9 a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Operations,
Food and Drug Administration, Three White Flint North, 10A-12M, 11601
Landsdown St., North Bethesda, MD 20852, 301-796-5733,
[email protected].
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3521), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's
[[Page 319]]
estimate of the burden of the proposed collection of information,
including the validity of the methodology and assumptions used; (3)
ways to enhance the quality, utility, and clarity of the information to
be collected; and (4) ways to minimize the burden of the collection of
information on respondents, including through the use of automated
collection techniques, when appropriate, and other forms of information
technology.
Imports and Electronic Import Entries
OMB Control Number 0910-0046--Revision
This information collection supports Agency regulations in 21 CFR
part 1, which govern FDA import activities. Specifically, the
regulations prescribe the required data elements that respondents must
submit when importing, or offering for import, an FDA-regulated article
into the United States. The data elements allow FDA to continue to meet
its responsibilities pertaining to current submission requirements
established by the U.S. Customs and Border Protection (CBP) related to
the submission of entry information in using its Automated Commercial
Environment (ACE) system, or any CBP-authorized electronic data
interchange (EDI) system. Respondents (ACE filers) submit important and
useful information about FDA-regulated products being imported or
offered for import into the United States so that we may effectively
and efficiently review products and determine their admissibility. In
addition, and as set forth in the regulations, certain product types
are subject to additional data elements (for example, 21 CFR 1.75
prescribes additional data elements for radiation-emitting products),
as well as those data elements applicable to all products.
We are revising the information collection to provide for a weekly
entry filing program (WEF). More detailed information on Foreign Trade
Zones (FTZ)/WEF, is available at https://www.fda.gov/industry/import-basics/foreign-trade-zonesweekly-entry-filing. The WEF program, which
is available for some FDA-regulated products, allows entry filers to
file a single entry estimating the amount of merchandise anticipated to
be removed from a FTZ and offered for U.S. consumption during a 7-day
period. To participate, we recommend respondents who wish to file a
weekly entry of FDA-regulated products with CBP, first request a
preliminary assessment from FDA. As part of this assessment, we
recommend submission of the following information:
FDA Import Division(s) \1\ with geographic oversight over
the FTZ location;
---------------------------------------------------------------------------
\1\ Some FTZs are covered by multiple Import Divisions.
---------------------------------------------------------------------------
Identification of whether products are manufactured or
stored in the FTZ;
FTZ site/subzone number and address;
Importer of Record (IOR) Facility Establishment Identifier
(FEI), if known;
Manufacturer FEI, if known; and
Port of entry.
The division information is necessary so that we can appropriately
route the submission within the Agency. Information on whether the
product is stored or manufactured in the zone is necessary for FDA to
determine the applicable admissibility requirements. The FTZ and port
information is necessary to ensure that basic requirements in 19 CFR
146 are met. The IOR and manufacturer FEI information is requested by
FDA to expedite the admissibility review. Requests to participate in
the WEF process are submitted to the FDA Import Division Office
covering the intended port of entry.
We are also revising the information collection to include our
Import Trade Auxiliary Communication System (ITACS), currently approved
under OMB control number 0910-0842. The ITACS is used by the import
trade community and was implemented to improve communication with FDA.
By utilizing ITACS, respondents to the information collection have the
ability to establish an account and electronically check the status of
FDA-regulated entries and lines, submit entry documentation, submit the
location of goods availability for those lines targeted for examination
by the FDA, and check the estimated laboratory analysis completion
dates for lines which have been sampled. For further information
regarding ITACS, please visit our website at https://www.fda.gov/industry/import-systems/itacs.
Description of Respondents: Respondents to the information
collection are domestic and foreign importers of FDA-regulated articles
being imported or offered for import into the United States and entry
filers who submit import entries on behalf of these importers.
We estimate the burden of the information collection as follows:
Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
21 CFR part 1; subpart D Number of responses per Total annual Average burden per response Total hours
respondents respondent responses
--------------------------------------------------------------------------------------------------------------------------------------------------------
Importers submission of data elements 85,480 10.05 859,074 0.05576 hours (3.346 minutes)..................... 47,902
(preparing the required information).
Entry filers (unique lines only)........ 3,419 12,196 41,698,124 0.04466 hours (2.68 minutes)...................... 1,862,238
WEF participants........................ 15 1 15 0.87 hours (52 minutes)........................... 13.05
ITACS; creation of account.............. 500 1 1 1................................................. 250
---------------------------------------------------------------------------------------------------------------
Total............................... ............ .............. 42,557,214 .................................................. 1,910,403
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital or operational and maintenance costs associated with the information collection.
An importer of record may be the owner or purchaser of the article
being imported or offered for import, or a customs broker licensed by
CBP under 19 U.S.C. 1641 who has been designated by the owner,
purchaser, or consignee to file the import entry. There is only one
importer of record per entry. We are updating the number of responses
and respondents since last OMB review of the information collection to
reflect the best data available to the Agency from January 1, 2018, to
December 31, 2018. Using these numbers, we update the number of
importers to 85,480 and the number of entry filers to 3,419. We retain
our currently approved estimate with regard to the number of responses
per respondent and time per response as representative of the industry
average.
Persons wishing to file weekly entries of FDA regulated products
are encouraged to provide the information identified so that FDA can
conduct a
[[Page 320]]
preliminary admissibility assessment of the associated products and
firms. This submission typically contains the information FDA requests
for multiple products (i.e., the respondent wishes to file weekly
entries for multiple products and submits the information for each
product together). Generally, submissions involving multiple products
are significantly less burdensome on a per-product basis. We estimate
that the burden for each product in a WEF submission is approximately
52.5 minutes, for a total of 13.125 hours annually. Depending on the
product and scale of submission, this estimated burden can fall to as
low as 15 minutes per product. The reason why this burden can be
significantly higher than an ACE submission is that the WEF submission
is done manually, typically through a spreadsheet. Filers submitting in
ACE typically use software that is developed to specifically automate
and expedite the entry submission process and allows filers to
automatically upload entry information. While the WEF submission
includes an initial one-time submission burden, we expect reduced
burden over a long term because filers can subsequently submit one
entry covering multiple withdrawals from the FTZ in any given seven-day
period.
Finally, since developing and implementing ITACS we believe that
most respondents to the information collection have realized the one-
time burden associated with creating an account and we have therefore
adjusted our estimate downward by 2,500 hours. At the same time, we
retain our estimate that 500 new accounts will be established annually
for a total of 250 burden hours.
Cumulatively these changes and adjustments result in a reduction in
annual responses by 40,112,208, and an increase in burden hours by
124,891. These changes and adjustments reflect the realization of one-
time burden associated with conforming to new CBP electronic reporting
requirements since last OMB approval of the information collection that
we believe no longer applies, together with the consolidation of
related information collection activities associated with ITACS.
Dated: December 30, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-28419 Filed 1-2-20; 8:45 am]
BILLING CODE 4164-01-P